Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial

https://www.thelancet.com/events/conferences/american-society-clinical-oncology?dgcid=hubspot_email_infocusalerts-oncology_feature_asco25&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-91LlyGdMVA9CGoGipJfoLokKPcRi1nAFNr0fMv7JOL0JpI51xpsPycw_hFnIo8oGygQybEB4PewG04EoSY_oj9MEIByg&_hsmi=371012952&utm_content=370484992&utm_source=hs_email